InfoBionics, BioTelemetry each claim win in patent spat

Both BioTelemetry (NSDQ:BEAT) and digital health startup InfoBionic celebrated victory in their patent fight with each other over wireless cardiac monitoring technology. But the battle is far from over. Pennsylvania-based BioTelemetry disclosed that the Massachusetts District Court stopped InfoBionic from making, using, marketing or selling in the U.S., or importing into the country, any of its first-generation MoMe Kardia system products. BioTelemetry also pledged to continue “pending patent infringement claims” against the company’s second-generation MoMe Kardia system, plus claims involving “misappropriation of BioTelemetry’s trade secrets.” BioTelemetry alleges that this happened after “one or more” ex-Biotelemetry executives and employees joined InfoBionic and took part in development of the MoMe Kardia system. Separately, however, Lowell-Mass.-based InfoBionic touted the court action as successfully resolving “obsolete patent claims.” The company also noted that as part of the agreement, it incurred no damages and “no monies were due” to BioTelemetry. InfoBionic won the FDA’s 510(k) clearance in March for a second-generation version of the system, which is designed to help diagnose cardiac arrhythmias through a 3-in-1 single piece device that acquires and stores ECG and motion data. That data, in turn, is transmitted through the compony’s cloud-based MoMe Software system for analysis. InfoBionic’s downplayed court action regarding ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Legal News BioTelemetry Inc. InfoBionic Source Type: news